Baxdrostat New Drug Application accepted under FDA Priority Review in the US for patients with hard-to-control hypertension

What we drew from this source

The claims Via News extracted from this document. We point to the source; we don't replace it.

• The substantial reduction in systolic blood pressure seen in the BaxHTN trial underscores baxdrostat's novel mechanism of action and its potential to bring innovation to a disease area that has seen limited progress in over two decades

  80% confidence

• If approved, baxdrostat could be the first aldosterone synthase inhibitor to receive regulatory authorization

  80% confidence

• Baxdrostat was generally well tolerated with a safety profile consistent with its mechanism of action. There were no unanticipated safety findings, and most adverse events were mild

  80% confidence

• This Priority Review demonstrates our commitment to advancing baxdrostat as a potential first- and best-in-class aldosterone synthase inhibitor for the millions of people living with hard-to-control hypertension as quickly as possible

  80% confidence

Data points we hold from this source